Search PubMed⌕ Search

Biomedical subjects

C Richard Conti

Publications and source records attributed to C Richard Conti.

At least 73 records · Page 4Linked to original sources
PubMed2003

Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina.

During myocardial ischemia, fatty acids are the principal source of energy, increasing myocardial oxygen consumption and making a decrease in coronary blood flow less well tolerated. Increasing glucose oxidation during myocardial ischemia may improve cardiac efficiency. The pFOX inhibitors have the potential to accomplish this. In 2003, I think we can look forward to learning more about this class of compounds called pFOX inhibitors. Perhaps they will provide us alternative therapies in our patients who have persistent chronic stable angina pectoris despite aggressive medical therapy and/or revascularization. It seems to methat this is an increasing problem, and it is particularly common in older patients who want to remain active, but whose chronic stable angina interferes with that lifestyle.

Acetanilides↗
PubMed2003

Angiotensin II blockade: a therapeutic strategy with wide applications.

Evidence now exists suggesting a pathologic role for angiotensin II in patients with cardiovascular disease and those with risk factors. Clinical trials such as the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE), the Heart Outcomes Prevention Evaluation Study (HOPE), the African American Study of Kidney Disease and Hypertension (AASK), and the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study have clearly demonstrated that blood pressure reduction is important in hypertension and diabetes. If this can be accomplished with agents that block the renin-angiotensin system, then additional clinical benefit will be achieved. Clinical data on angiotensin-converting enzyme inhibitors (ACEIs) are well established, while emerging data on the use of angiotensin II receptor blockers (ARBs) continue to grow. There is evidence supporting the concept of angiotensin II escape in the presence of ACEIs. The question that remains to be answered is whether a combination of both agents (ACEIs and ARBs) can improve clinical outcomes. Ongoing clinical trials will answer this question.

Angiotensin II↗
PubMed2002

Clinical endpoints.

Explore the source record for details and available documents.

Cardiovascular Diseases↗
PubMed2002

Detection of viable myocardium using coronary angiography and ventriculography.

In 2002, coronary angiography is the only way to assess precisely the combination of proximal stenoses, distal target vessels, collaterals, microcirculation, and TIMI antegrade flow. At the time of coronary angiography, global LV function is best determined using biplane ventriculography in order to correlate wall motion with coronary stenoses, distal target vessels, microcirculation, collaterals, and antegrade TIMI flow. This can be done under resting conditions after nitrates or after postextrasystolic potentiation. The absolute diagnosis of viability can only be made retrospectively. Large areas of ischemic viable myocardium should improve contraction after revascularization, decrease symptoms, and prolong survival.

Coronary Angiography↗